A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
Hayley Nehoff(University of Otago), Khaled Greish(University of Otago)
Cited by 32
Related Papers
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
|International Journal of Nanomedicine|2016|20
The Influence of Drug Loading on Caveolin-1 Mediated Intracellular Internalization of Doxorubicin Nanomicelles in vitro
|Journal of Nanomedicine & Nanotechnology|2014|14